Clinical trials: Mild-to-moderate Ulcerative Colitis
Ulcerative Colitis
GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis
The aim of this double blind, placebo controlled, study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X, and to provide preliminary pharmacokinetics and safety/tolerability of 14…
- Trial name
- NCT00457171
- Testing
- GI-270384
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who are in remission.
- Trial name
- PACE (NCT02093663)
- Testing
- MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose)
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Shire
Ulcerative Colitis
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis
This study will examine the safety and efficacy in subjects with mild to moderate ulcerative colitis, as measured by Modified Mayo Score, Modified Baron Score, IBDQ, calprotectin and other assessments.
- Trial name
- NCT01839214
- Testing
- VB-201 160mg
- Where
- 3 sites in Bulgaria, Hungary and 1 more
- Volunteers
- 112 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Ulcerative Colitis
Transcutaneous Electrical Acustimulation in the Treatment of Mild to Moderate Ulcerative Colitis
The aim of this study was to evaluate the efficacy and safety of transcutaneous electrical acustimulation in patients with mild to moderate ulcerative colitis.
- Trial name
- NCT06231264
- Testing
- transcutaneous electrical acustimulation at treatment sites
- Where
- 4 sites in China
- Volunteers
- 96 people
- Sponsor
- Xijing Hospital
Ulcerative Colitis
A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase 1b study to evaluate the safety and tolerability of MB310 given to patients who have active mild-to-moderate ulcerative colitis.
- Trial name
- COMPOSER-1 (NCT06582264)
- Testing
- MB310, Vancomycin
- Where
- 22 sites in Austria, Bulgaria and 3 more
- Volunteers
- 29 people
- Sponsor
- Microbiotica Ltd
Ulcerative Colitis
Acupuncture for Symptom Relief in Adults with Mild to Moderate Ulcerative Colitis
Ulcerative colitis (UC) is one of the two primary forms of inflammatory bowel disease. This condition is characterized by continuous mucosal inflammation that begins in the rectum and extends proximally throughout the colon.
- Trial name
- NCT06615765
- Testing
- Acupuncture
- Volunteers
- 64 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Ulcerative Colitis
Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.
E.coli Nissle 1917 (Mutaflor®) is equivalent to mesalazine in preventing disease relapse in ulcerative colitis. However, data on ability of E.coli Nissle 1917 (Mutaflor®) to induce remission compared with placebo is limited.
- Trial name
- NCT04969679
- Testing
- E. coli Nissle 1917 (Mutaflor®)
- Where
- South Korea
- Volunteers
- 134 people
- Sponsor
- Kangbuk Samsung Hospital
Ulcerative Colitis
Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)
The purpose of this study is to evaluate the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) versus Asacol 2.4 g/day (400 mg tablet
- Trial name
- ASCEND I (NCT00577473)
- Testing
- mesalamine
- Where
- 44 sites in United States
- Volunteers
- 301 people
- Sponsor
- Warner Chilcott
Ulcerative Colitis
ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis
This is a multi-center trial to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis (UC).
- Trial name
- NCT00063414
- Testing
- Alicaforsen
- Where
- United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Ulcerative Colitis
Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis
The purpose of this study is to compare the maintenance of mild to moderate ulcerative colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day versus placebo.
- Trial name
- NCT00767728
- Testing
- Granulated mesalamine
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis
Ulcerative colitis (UC) is an immune mediated chronic inflammatory bowel disease that results at least in part of an abnormal immune response to environmental factors including the intestinal microbiota.
- Trial name
- EMMENTAL (NCT02488954)
- Testing
- Probiotics in the form of cheese portion
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Rennes University Hospital
Ulcerative Colitis (UC)
Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis
The goal of the study is to evaluate strategies that target the microbiota for the treatment of Ulcerative Colitis , This study will involve a novel diet that the investigators developed , based on the hypothesis that UC involves…
- Trial name
- NCT02345733
- Testing
- Ulcerative Colitis Diet, Antibiotic cocktail
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 20 people
- Sponsor
- Prof. Arie Levine
Left-Sided Ulcerative Colitis, Proctosigmoiditis
Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis
PUR 0110 is a 100% natural novel investigational medicinal product that has been demonstrated in several in vitro and in vivo pharmacology studies to have potent anti-inflammatory, anti-oxidative and immunomodulatory effects.
- Trial name
- NCT01149707
- Testing
- PUR 0110 Rectal Enema 250 mg, PUR 0110 Rectal Enema 500 mg, PUR 0110 Rectal Enema 1000 mg
- Where
- 6 sites in Germany
- Volunteers
- 34 people
- Sponsor
- PurGenesis Technologies Inc.
Ulcerative Colitis
Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis
This is a double-blind, randomized, placebo controlled study to assess the beneficial effects of food supplementation with VSL#3 as a support to standard pharmaceutical therapy in patients affected by mild to moderate active…
- Trial name
- NCT00951548
- Testing
- VSL#3
- Where
- 13 sites in Italy
- Volunteers
- 144 people
- Sponsor
- VSL Pharmaceuticals
Mild-to-moderate Ulcerative Colitis
Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study)
The purpose of this study is to provide evidence that a therapy of Ulcerative Colitis (UC) disease adjusted on tight monitoring of non-invasive parameters, such as clinical symptoms and faecal calprotectin (FC) (substance that is…
- Trial name
- OPTIMISE (NCT04340895)
- Testing
- Faecal Calprotectin Home Test, PRO-2 Scoring
- Where
- 42 sites in Czechia, Hungary and 4 more
- Volunteers
- 250 people
- Sponsor
- Ferring Pharmaceuticals
Inflammatory Bowel Diseases, Crohn Disease
Real Life Remote Monitoring of Mild, Moderate and Severe Infectious Complications in IBD by Patient Reported Assessment
Inflammatory bowel disease (IBD) is a chronic relapsing immune mediated inflammatory disease (IMID) of the gastrointestinal tract. Like all IMIDs (e.g.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, IBD
- Trial name
- NCT04151420
- Testing
- Remote monitoring tool (infections questionnaire) validation
- Where
- 2 sites in Netherlands
- Volunteers
- 584 people
- Sponsor
- Maastricht University Medical Center
Ulcerative Colitis
Safety and Efficacy of Heterologous FMT by SQIMC-md Capsule in Mild-moderate Ulcerative Colitis Patients
This study aims to assess the safety and efficacy of heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md) in mild-moderate ulcerative colitis…
- Trial name
- SQIMC-md (NCT04034758)
- Testing
- Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
- Volunteers
- 99 people
- Sponsor
- Tongji Hospital
Ulcerative Colitis
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects…
- Trial name
- NCT04314375
- Testing
- Low Dose Budesonide, High Dose Budesonide
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients
This study is a randomized double-blind clinical trial that intends to evaluate the efficacy and safety of LGG administration at two different doses, for 1 month, in ulcerative colitis (UC) patients with mild-moderate disease…
- Trial name
- LGGinUC (NCT04102852)
- Testing
- Lactobacillus rhamnosus GG ATCC 53103
- Where
- Italy
- Volunteers
- 76 people
- Sponsor
- San Giovanni Addolorata Hospital
Ulcerative Colitis
Prebiotics in Reducing Inflammation and Clinical Endpoints in Ulcerative Colitis (PRInCE-UC)
The community of microbes living in the gut is called the 'gut microbiome'. Changing this could be an exciting new way of treating people living with ulcerative colitis (UC). UC is a type of inflammatory bowel disease.
- Trial name
- PRInCE-UC (NCT06050811)
- Testing
- 2'-Fucosyllactose
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Royal Berkshire NHS Foundation Trust